Google
LNTH Stock Price & Analysis — Lantheus Holdings Inc (Healthcare >> Drug Manufacturers - Specialty & Generic)
LNTH FAQ
What is LNTH's P/E ratio?
Lantheus Holdings Inc (LNTH) currently trades at a P/E ratio of 23.57.
What is LNTH's ROE?
Lantheus Holdings Inc reports a Return on Equity (ROE) of 23.02%.
What is LNTH's dividend yield?
Lantheus Holdings Inc offers a dividend yield of 0.00%.
What is LNTH's Quality Score?
Our AI rates LNTH's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LNTH?
Our AI Timing Score for LNTH is 71 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LNTH belong to?
Lantheus Holdings Inc is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange
LNTH AI Analysis Summary
Our AI summary for LNTH: Lantheus Holdings Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 23.57, ROE of 23.02%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 71/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 99.64
Price
-1.36
(-1.35%)
Day Change
|
|
|---|
LNTH, the overall quality is good ( Quality = 77) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
1024
|
| Magic Formula Rank by ROE |
1024
|
| Magic Formula Rank by ROIC |
1059
|
| Price | 99.64 |
| PBV / Sector |
5.42 / 3.22
|
| Earning Per Share | 4.23 |
| PE / Sector |
23.57 / 29.79
|
| PEG or PE/Growth / Sector |
0.07 / 0.13
GREAT
|
| Average 1M Daily Value |
94.71 M
|
| Average 1W Daily Value |
138.33 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
56% |
| Ability to Make Profit |
|
70% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:07 |
| Symbol | LNTH |
| Name | LANTHEUS HOLDINGS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 65.11 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,575.71 / 10,754.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 201 Burlington Road, Bedford, MA, United States, 01730
Phone: 978 671 8001
Website: https://www.lantheus.com
Employees: 1,193
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Drug Manufacturers - Specialty & GenericAnalysed on the same criteria, ordered by market cap